In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B‐cell lymphoma ( DLBCL ) cell lines with different levels of expression of CD20
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20033 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Joshua S Bray und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antigens, CD20, Lymphoma, Large B-Cell, Diffuse, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leicester Experimental Cancer Medicine Centre (ECMC), Scott Waudby Trust, Medical Research Council.
Abstract (Originalsprache)
Although CD20xCD3 bispecific antibodies (BsAbs) have demonstrated transformational activity in diffuse large B‐cell lymphoma (DLBCL), some patients fail to respond and others relapse. To begin to explore possible limitations, we compared the in vitro activity of four CD20xCD3 biosimilar BsAbs against four DLBCL cell lines with CD20 expression ranging over a 100‐fold. All four biosimilar BsAbs demonstrated superior in vitro activity to rituximab, with biosimilar glofitamab consistently being the most potent. Moreover, biosimilar glofitamab and odronextamab retained significant activity in the presence of low‐level CD20 expression. Finally, one DLBCL cell line exhibited intrinsic resistance to all four CD20xCD3 BsAbs despite inducing marked T‐cell and NK‐cell activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
- Respiratory Sciences, University of Leicester, Glenfield Hospital, Leicester, UK.
- Department of Oncology, University Hospitals Leicester, Leicester, UK.
ORCID-Profile: Sandrine Jayne, Martin J S Dyer, Harriet S Walter
Förderung
- Leicester Experimental Cancer Medicine Centre (ECMC)
- Scott Waudby Trust
- Medical Research Council
- Cancer Research UK
Zitieren
APA
Bray, J. S., Thomas, G. R., Smith, V. M., Wright, A., Jayne, S., Dyer, M. J. S., & Walter, H. S. (2025). In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B‐cell lymphoma ( DLBCL ) cell lines with different levels of expression of CD20. British Journal of Haematology. https://doi.org/10.1111/bjh.20033
Vancouver
Bray JS, Thomas GR, Smith VM, Wright A, Jayne S, Dyer MJS, et al. In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B‐cell lymphoma ( DLBCL ) cell lines with different levels of expression of CD20. British Journal of Haematology. 2025. doi:10.1111/bjh.20033
BibTeX
@article{Bray2025,
author = {Bray, Joshua S and Thomas, Gethin R and Smith, Victoria M and Wright, Adam and Jayne, Sandrine and Dyer, Martin J S and Walter, Harriet S},
title = {In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B‐cell lymphoma ( DLBCL ) cell lines with different levels of expression of CD20},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20033}
}
EUVIMED